Search
Displaying 291–300 of 757 for “retinitis clinical trial”
-
Retinal Regeneration: Releasing Your Inner Salamander
Research NewsMany research groups from around the world are investigating ways to create new photoreceptors from stem cells for transplantation into the retina for vision restoration.
-
ARVO 2014: European Collaboration Developing Cross-Cutting, Vision-Saving Therapies
Research NewsSimply put, they’re creating therapies that can save vision in as many people as possible, independent of the genetic cause of disease.
-
Nobel Prize Winners Have Big Impact on Emerging Retinal Treatments
Research NewsThe 2012 Nobel Medicine prize winners are having an enormous impact on sight-saving retinal research.
-
Choroideremia Gene Therapy Moves into Phase 3 Human Study
Research NewsNightstar Therapeutics, a retinal-disease, gene-therapy development company in the UK, is advancing its emerging gene therapy for choroideremia into a Phase 3 clinical trial known as STAR. The study will enroll approximately 140 patients at 18 clinical sites in the US, Europe, Canada, and South America.
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Research NewsProof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
FDA Wins Case against Stem-Cell Clinic that Blinded Patients with Bogus Treatment
Research NewsA federal court ruled that the FDA has regulatory authority over these stem-cell procedures and the power to halt them.
-
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
In the PressThe Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
Clinical Research Fellowship Award (CRFA)
Objective/Goal: The program will provide funding for post-residency clinical fellowships in inherited orphan retinal degenerations. The goal is to increase the number of clinician-scientists with expertise and commitment to provided clinical care to patients with inherited orphan retinal degenerations. This program supports up to three post-residency clinicians for one (1) year. $65,000/year
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
